Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28514523 | 0.80 | PBRM1 (0.46) | PBRM1AHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL20598763 | 0.78 | NPC1 (0.40) | RAB9ANPC1SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL28528659 | 0.78 | CYP2A6 (0.42) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL29609448 | 0.78 | RAB9A (0.53) | PBRM1AHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29025171 | 0.76 | CYP1A2 (0.41) | RAB9ANPC1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL581207 | 0.76 | NPC1 (0.41) | RAB9ANPC1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL29240236 | 0.75 | CYP2A6 (0.39) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL28457966 | 0.74 | PBRM1 (0.47) | PBRM1AHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL19295106 | 0.74 | PIN1 (0.41) | MAPK1ALDH1A1L3MBTL1HPGDTDP1 | |
| SCHEMBL11916270 | 0.74 | CYP1A2 (0.51) | RAB9ANPC1SMN1; SMN2MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778919-B2 | Cyclic anilino—pyridinotriazines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| CN-101341138-B | Cyclic anilino-pyridinotriazines as GSK-3 inhibitors | JANSSEN PHARMACEUTICA NV | 2012-11-14 | — | — | CN | disclosed |
| US-20100222574-A1 | CYCLIC ANILINO - PYRIDINOTRIAZINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-1904461-B1 | CYCLIC ANILINO-PYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-12 | — | — | EP | disclosed |
| CN-101341138-A | Cyclic anilino-pyridinotriazines as GSK-3 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-07 | — | — | CN | disclosed |
| EP-1904461-A2 | CYCLIC ANILINOPYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007003525-A2 | CYCLIC ANILINO-PYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222574-A1 | CYCLIC ANILINO - PYRIDINOTRIAZINES | NR4A1, NR4A2, NR5A2 | PBRM1 1719/4885AHR 59/4885RAB9A 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.